EUCTR2012-005418-20-NL进行中（未招募）1 期
A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven macular edema (ME)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 178
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Diagnosis of active ME secondary to any causes (for adult patients: except DME, AMD and
- •RVO) that is primary, chronic (i.e., ME is present for > 3 months) or recurrent, confirmed by
- •at least one of three following criteria::
- •Presence of posterior pole changes compatible with active ME seen by fundus
- •ophthalmoscopy, biomicroscopy and fundus photography
- •Presence of leakage from ME seen by fluorescein angiography (FA)
- •Presence of intra-retinal fluid/cysts seen by optical coherence tomography (OCT)
- •BCVA must be between = 24 and = 83 letters tested at 4 meters starting distance using
- •ETDRS-like visual acuity charts (approximate Snellen chart equivalents of 20/25 and 20/320)
- •in the study eye
- •Visual loss in the study eye should be mainly due to the presence of any eligible types of ME
- •(for adult patients: non-DME, non-AMD and non-RVO) based on ocular clinical, as well as FA
- •and OCT findings
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 10
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 157
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •For both eyes
- •Active diabetic retinopathy, active ocular/periocular infectious disease or active severe
- •intra-ocular inflammation (e.g., anterior chamber cells (ACC) >2+ and/or vitreous haze
- •(VH) >2+). Rescreening is permitted after intra-ocular inflammation is successfully
- •treated with anti-inflammatory therapy that does not compromise eligibility
- •Confirmed intraocular pressure (IOP) = 25 mmHg for any reason
- •Neovascularization of the iris or neovascular glaucoma
- •Inability to obtain fundus photographs, fluorescein angiograms or OCT images of
- •sufficient quality to be analyzed
- •For study eye
- •ME secondary to DME, AMD or RVO (for adult patients only). RAP lesions are
- •exclusionary in patients 50 years of age or older
- •Ocular disorders that could confound interpretation of study results, compromise visual
- •acuity or require medical or surgical intervention during the 12-month study period. These
- •include for example:
- •Presence or history of retinal detachment, macular hole, epi-retinal membrane (if the
- •membrane is involving the fovea)
- •Presence of cataract, leading to marked visual impairment and/or requiring surgery
- •during the study
- •Presence of vitreomacular traction (VMT) as the primary reason for the ME in the
- •opinion of the investigator
- •Diagnosis of retinitis pigmentosa (RP)
- •Diagnosis of Central Serous Chorioretinopathy (CSC, CSR)
- •Any type of advanced, severe or unstable ocular disease or its treatment, that could
- •interfere with the primary and/or secondary outcome evaluations including any medical
- •condition that could be expected to progress, recur, or change to such an extent that it
- •could bias the assessment of the clinical status of the patient to a significant degree or put
- •the patient at special risk.
- •ME with a high likelihood of spontaneous resolution (e.g., central serous chorioretinopathy
- •(CSC) or pseudophakic ME) unless the ME persists for > 3 months or has not improved
- •upon topical treatment with steroids or NSAIDsHistory of laser photocoagulation with
- •involvement of the macular area at any time
- •Verteporfin photodynamic therapy (vPDT) at any time
- •History of intraocular treatment with any anti-angiogenic drugs within 6 months of the
- •baseline visit (e.g., bevacizumab [Avastin®], aflibercept [Eylea®], pegaptanib [Macugen®],
- •ranibizumab [Lucentis®])
- •History of intravitreal treatment with steroids, e.g. triamcinolone within 6 months prior to
- •History of treatment with intravitreal implants (e.g., Illuvien®, Ozurdex®, Retisert®) at any
研究者
相似试验
进行中（未招募）
不适用
A 12-month study to evaluate the efficacy and safety of injections of 0.5 mg ranibizumab into the eye of patients with impaired vision which is caused by new vessels (neovascularization) in the choroid and for which ranibizumab may have a positive impactVisual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)MedDRA version: 17.0Level: LLTClassification code 10060837Term: Choroidal neovascularizationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 17.0Level: PTClassification code 10047571Term: Visual impairmentSystem Organ Class: 10015919 - Eye disordersEUCTR2012-005417-38-SKovartis Pharma Services AG187
进行中（未招募）
1 期
A 12-month study to evaluate the efficacy and safety of injections of 0.5 mg ranibizumab into the eye of patients with impaired vision which is caused by new vessels (neovascularization) in the choroid and for which ranibizumab may have a positive impactVisual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)MedDRA version: 17.0Level: LLTClassification code 10060837Term: Choroidal neovascularizationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 17.0Level: PTClassification code 10047571Term: Visual impairmentSystem Organ Class: 10015919 - Eye disordersEUCTR2012-005417-38-BEovartis Pharma Services AG187
进行中（未招募）
不适用
A 12-month study to evaluate the efficacy and safety of injections of 0.5 mg ranibizumab into the eye of patients with impaired vision which is caused by new vessels (neovascularization) in the choroid and for which ranibizumab may have a positive impactEUCTR2012-005417-38-LTovartis Pharma Services AG187
已完成
3 期
Study to evaluate the efficacy and safety of 0.5 mg in adult patients with visual impairment due to choridal neovascularization (CNV).CTRI/2014/08/004891ovartis Healthcare Pvt Ltd187
进行中（未招募）
1 期
A 12-month study to evaluate the efficacy and safety of injections of 0.5 mg ranibizumab into the eye of patients with impaired vision which is caused by new vessels (neovascularization) in the choroid and for which ranibizumab may have a positive impactVisual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)MedDRA version: 19.0Level: LLTClassification code 10060837Term: Choroidal neovascularizationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 19.0Level: PTClassification code 10047571Term: Visual impairmentSystem Organ Class: 10015919 - Eye disordersEUCTR2012-005417-38-DEovartis Pharma Services AG187